Provides physicians with the capacity to implant Ventricular Assist Devices (VADs) in patients with congestive heart failure (CHF) and a weak left ventricular wall.
Flow cytometry-based method for predicting post-surgical cardiovascular events.
Measuring endotrophin (ProC6) in plasma predicts the risk of death, heart failure admission, and composite cardiovascular events in HFpEF patients.
Non-replicating viral delivery of shVASH1 to treat heart failure.
A hydrogel that combines conductive additives with the strength of dynamic bonds to create a naturally flexible and adhesive electrode.
HDAC and DNMT Inhibitors such as Trichostatin A (TSA) and 5-aza-cytidine are preventative therapies and reduce myocardial infarct volume following cardiac events
Tool that evaluates the utility of various tests for coronary artery disease, saving time by allowing non-cardiologists to order an appropriate test.
Platform technology for targeted drug delivery using red blood cells for transport.
Professors from Penn Cardiothoracic Surgery have designed a single device that is able to replace the aortic valve and repair the ascending aorta in one procedure.
Indicators for treatment of bicuspid aortic valve and aortopathies.